Fertility After STI or Genital Infection

Many treated infections do not cause lasting fertility problems. Risk rises when infections are untreated, recurrent, severe, or involve the fallopian tubes, testes, epididymis, prostate, or uterus.

In women, PID can scar tubes and raise ectopic pregnancy risk. In men, epididymitis, prostatitis, mumps orchitis, varicocele plus inflammation, or high fever can reduce semen quality temporarily or persistently.

Recovery focuses on correct treatment, partner treatment, retesting when recommended, inflammation control, avoiding reinfection, and semen or tubal evaluation if pregnancy does not occur after an appropriate trying interval.

Fertility care should include both partners. Testing only one person misses half the picture and can delay effective treatment.

How infections can affect fertility

Some STIs, particularly untreated chlamydia and gonorrhea, can cause scarring in the reproductive tract—blocked fallopian tubes in women or affected sperm transport in men—that reduces fertility. The risk rises with repeated or untreated infections, which is a key reason prompt treatment and screening matter so much.

Steps if you are concerned

A past infection does not necessarily mean fertility problems, and many people conceive without difficulty. If you have had recurrent infections or are struggling to conceive after a year of trying (or six months if over 35), a fertility evaluation can assess tubal health and sperm quality and outline options, many of which are effective.

How STIs Disrupt the Reproductive System Over Time

Sexually transmitted infections affect fertility through several mechanisms, and understanding these pathways helps demystify what can feel like an inexplicable diagnosis. Chlamydia and gonorrhoea are the primary bacterial culprits in tubal damage, but other infections — including Mycoplasma genitalium, trichomonas, viral infections such as human papillomavirus (HPV), and herpes simplex virus (HSV) — can each interact with reproductive health in distinct ways. The unifying theme is that untreated or inadequately treated infection triggers inflammation that, over time, causes structural or functional changes in the organs of reproduction.

In men, infections can cause epididymo-orchitis — inflammation of the epididymis and testes — which can scar the delicate tubules through which sperm must travel to mature and exit. Bilateral epididymal obstruction is a recognised cause of obstructive azoospermia (no sperm in the ejaculate). Infections can also impair sperm function through oxidative stress even without causing structural obstruction, reducing motility and increasing DNA fragmentation — both of which reduce fertilisation potential.

Chlamydia: The Silent Fertility Threat

Chlamydia trachomatis is the most commonly reported bacterial STI worldwide and is rightly called silent because the majority of infections — up to 70–80 % in women and 50 % in men — produce no noticeable symptoms. In women, untreated chlamydia can ascend to the fallopian tubes and cause salpingitis (tube inflammation) that progresses to tubal scarring over months or years. The protein MOMP (major outer membrane protein) of chlamydia cross-reacts with human heat-shock proteins, prompting a misdirected immune attack that perpetuates tubal inflammation long after the original bacteria are gone.

In men, chlamydia can cause non-gonococcal urethritis, epididymitis, and potentially impair sperm parameters. Research has linked chlamydia antibodies in male partners to lower fertilisation rates in IVF cycles, suggesting sperm function is affected beyond simple obstruction. The key takeaway for both sexes is that routine annual screening — or screening with every new sexual partner — enables early detection and treatment before fertility damage accumulates.

Gonorrhoea and Mycoplasma genitalium

Gonorrhoea (Neisseria gonorrhoeae) has a faster and more aggressive course than chlamydia. In women, it rapidly invades tubal epithelium and can cause severe PID within days. Even short-duration infection can leave significant scarring. The emergence of antimicrobial-resistant gonorrhoea strains in recent years has made treatment more complicated — some strains respond only to injectable ceftriaxone — which underscores the importance of culture and sensitivity testing rather than assuming standard oral regimens will work.

Mycoplasma genitalium is a smaller, slower-growing organism that has only recently been recognised as a significant cause of cervicitis, endometritis, and salpingitis. It is associated with tubal-factor infertility and recurrent miscarriage, and it is not detected by standard STI panels at many clinics — you may need to specifically request testing. It is also inherently resistant to first-line azithromycin in a growing proportion of cases, requiring moxifloxacin instead. If you have unexplained infertility and a history of pelvic symptoms, ask your clinician whether M. genitalium testing has been performed.

Viral Infections and Reproductive Impact

HPV does not directly cause infertility, but high-risk strains that lead to cervical dysplasia or cervical cancer, and the treatments used to manage them — including loop excision (LLETZ) — can affect cervical length and mucus production. Significant removal of cervical tissue increases miscarriage risk in subsequent pregnancies due to cervical incompetence. HPV vaccination prevents the high-risk strains and is recommended for adolescents but is available up to age 45 or older in many countries for those who were not previously vaccinated.

Herpes simplex virus (HSV) does not damage tubal or uterine structure in most people, but primary HSV infection during early pregnancy is associated with a small increased risk of miscarriage and neonatal herpes. In men, HSV DNA has been detected in semen and is associated in some studies with reduced sperm motility. These impacts are modest compared to bacterial STIs, but they illustrate why comprehensive STI management is part of preconception care.

Human immunodeficiency virus (HIV) itself does not prevent conception, and with modern antiretroviral therapy many HIV-positive individuals have normal fertility outcomes. However, HIV can be associated with altered menstrual function, accelerated ovarian aging in some populations, and increased susceptibility to co-infections that do damage fertility directly. Couples with HIV should work with both an infectious disease specialist and a reproductive medicine team when planning pregnancy.

Post-Infection Fertility Assessment: What to Expect

If you have a history of STI or pelvic infection and are concerned about fertility, a structured assessment provides clarity. For women, this typically includes a transvaginal ultrasound to evaluate the uterus and ovaries, a tubal patency test such as hysterosalpingogram (HSG) or HyCoSy, an ovarian reserve assessment (antral follicle count and AMH level), and a review of menstrual cycle regularity. For men, a semen analysis — measuring count, motility, morphology, and volume — is the starting point, with sperm DNA fragmentation testing if initial results are abnormal.

These investigations establish a baseline before attempts to conceive, allowing targeted treatment rather than a year of unexplained failure. A woman with confirmed bilateral tubal occlusion after infection, for example, will not conceive naturally and would benefit from early IVF referral rather than months of timed intercourse. Identifying the specific obstacle avoids wasted time and emotional toll.

Treatment Options When Infection Has Impaired Fertility

When tubal damage from infection has caused partial obstruction, laparoscopic salpingostomy (surgically opening the tube) or fimbrioplasty (reconstructing the fimbrial end) may restore patency in selected cases — typically when the tube is mildly hydrosalpinx and not extensively scarred. However, success rates for surgical tubal repair have declined relative to IVF success rates, and for most women with significant tubal disease, IVF is more cost-effective and time-efficient. The decision depends on the woman's age, the degree of damage, and available resources.

In men with obstructive azoospermia from epididymal scarring, microsurgical epididymal sperm aspiration (MESA) or percutaneous epididymal sperm aspiration (PESA) can retrieve sperm for use in ICSI. Even when the epididymis is too scarred for retrieval, testicular sperm extraction (TESE) from the testicular tissue itself is often possible. These techniques, combined with ICSI, mean that men with post-infection obstructive azoospermia can still father biological children.

Prevention as the Most Powerful Fertility Protection

No fertility treatment, however advanced, fully restores the reproductive system to its pre-infection state. Prevention is therefore immeasurably more powerful than any intervention after the fact. Consistent and correct condom use reduces STI transmission risk substantially. Regular STI screening — annually or with each new partner — allows early detection when infections are still asymptomatic and easily treated. Partner notification ensures the full chain of transmission is broken. HPV vaccination provides durable protection against the strains most likely to cause cervical disease.

Discussing STI history and testing openly with new partners, though socially uncomfortable for many people, is one of the most meaningful acts of mutual care. Normalising these conversations in relationships is a cultural shift that has tangible public health and fertility consequences. Educational programmes, like those provided through platforms such as Aegis Education, play a real role in equipping individuals with the knowledge and confidence to have these conversations.

Frequently Asked Questions

Q: I was treated for chlamydia years ago and never had symptoms. Could it have affected my fertility? A: Possibly, yes. Subclinical chlamydia can cause tubal damage without symptoms. The best way to assess this is a tubal patency test (HSG or HyCoSy) when you are planning pregnancy or if you have been trying for six or more months without success. Many women in this situation have perfectly patent tubes; others have partial scarring that can be managed with IVF. Testing provides an answer rather than uncertainty.

Q: My partner had gonorrhoea in the past. Should he get a semen analysis before we try to conceive? A: Yes, especially if he had symptoms of epididymitis (testicular pain, swelling) at the time or if gonorrhoea was inadequately treated. A semen analysis is a straightforward, non-invasive test that provides a great deal of information. If results are normal, you can proceed with confidence. If there is a sperm parameter abnormality, addressing it early saves months of unexplained trying.

Q: Does having had an STI mean I need to tell a fertility clinic? A: Absolutely. Fertility clinics need a full medical and sexual health history to interpret investigations correctly and design the right treatment plan. A history of PID, for example, directs them immediately toward tubal patency testing. Withholding this information can lead to a delayed diagnosis and inappropriate management.

Q: Can antiviral medication for herpes affect sperm or egg quality? A: Standard herpes antivirals — aciclovir, valaciclovir, famciclovir — are not known to cause significant reproductive harm at therapeutic doses. If you are planning pregnancy and are on suppressive antiviral therapy, discuss the specific medication with your clinician, but in most cases these drugs are considered compatible with attempts to conceive.